) and partner
Astellas Pharma Inc.
) continue to come out with positive data on their prostate
cancer therapy, Xtandi (enzalutamide). The companies presented
final results from the phase III randomized, double-blind,
placebo-controlled, multi-national PREVAIL study which was
conducted in chemo-naïve metastatic prostate cancer patients who
had failed androgen deprivation therapy and had few or no
The results are pretty impressive with Xtandi reducing the
risk of death by 29% compared to placebo. Moreover, the risk of
radiographic progression or death was cut by 81% in the Xtandi
arm. A 17-month delay in the time to initiation of chemotherapy
was observed in the Xtandi arm.
Medivation also reported that most of the men with soft tissue
metastatic disease had objective responses in the Xtandi arm
compared to placebo (58.8% versus 5%) - complete response was
observed in 19.7% of patients in the Xtandi arm compared to just
1% in the placebo arm.
The median time to PSA progression was extended from 2.8
months in the case of placebo to 11.2 months in the case of
Xtandi. About 78% of patients in the Xtandi arm saw a PSA decline
of ≥50% compared to less than 4% in the placebo arm.
Xtandi is currently approved for the treatment of patients
with metastatic castration-resistant prostate cancer who have
previously received docetaxel.
Medivation had presented encouraging interim data from the
PREVAIL study last year. The recently released full data confirms
the interim results and will allow the companies to go ahead and
file for approval shortly. Expansion into the pre-chemo setting
will be a major positive for Medivation. The 17-month delay in
the time to initiation of chemotherapy should help Xtandi gain
share once it is approved for the pre-chemo patient
Medivation is a Zacks Rank #1 (Strong Buy) stock. Some other
stocks worth considering in the health care sector include
). Both are Zacks Rank #1 stocks.
AFFYMETRIX INC (AFFX): Free Stock Analysis
ACTELION LTD (ALIOF): Get Free Report
ASTELLAS PHARMA (ALPMY): Get Free Report
MEDIVATION INC (MDVN): Free Stock Analysis
To read this article on Zacks.com click here.